Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP
18/04/2026 06:04
April 18 (Reuters) - argenx SE ARGX.BR: ARGENX BRINGS NEUROMUSCULAR LEADERSHIP TO AAN 2026 WITH NEW DATA SUPPORTING BROADER VYVGART USE ACROSS MG AND CIDP ARGENX SE - PHASE 3 ADAPT OCULUS STUDY MET ITS PRIMARY ENDPOINT Source text: ID:nGNEccGTtJ Further company coverage: ARGX.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on argenx SE
See all newsBrief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles
Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP